Trilogy Capital Inc. Has $3.73 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Trilogy Capital Inc. reduced its holdings in Gilead Sciences by 10.9% in the first quarter, now owning 33,247 shares valued at approximately $3.73 million.
• Analysts have mixed reviews on Gilead Sciences, with a consensus rating of "Moderate Buy" and an average price target of $111.38 among surveyed brokerages.
• Gilead reported $1.81 EPS, exceeding estimates, but its quarterly revenue decreased by 0.3% compared to the previous year, amounting to $6.67 billion.

Trilogy Capital Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,247 shares of the biopharmaceutical company's stock after selling 4,060 shares during the quarter. Trilogy Capital Inc.'s holdings in Gilead Sciences were worth $3,725,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the first quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Core Alternative Capital lifted its stake in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new stake in Gilead Sciences during the first quarter worth $39,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Price Performance

Shares of GILD opened at $113.20 on Friday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The stock has a market capitalization of $140.81 billion, a PE ratio of 23.83, a PEG ratio of 0.73 and a beta of 0.29. The company has a 50 day moving average price of $109.63 and a 200-day moving average price of $105.71. Gilead Sciences, Inc. has a fifty-two week low of $72.43 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.32) EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,000 shares of company stock valued at $7,844,775. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.